| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.
|
J Hepatol
|
2013
|
5.64
|
|
2
|
Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
|
Gastroenterology
|
2014
|
3.52
|
|
3
|
Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis.
|
Aliment Pharmacol Ther
|
2014
|
2.18
|
|
4
|
Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir.
|
Aliment Pharmacol Ther
|
2013
|
2.15
|
|
5
|
Effectiveness of telaprevir and boceprevir triple therapy for patients with hepatitis C virus infection in a large integrated care setting.
|
Dig Dis Sci
|
2014
|
1.63
|
|
6
|
Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes.
|
J Infect Dis
|
2015
|
1.56
|
|
7
|
Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET.
|
J Hepatol
|
2014
|
1.36
|
|
8
|
Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C.
|
J Viral Hepat
|
2014
|
1.16
|
|
9
|
Emerging therapies for hepatitis C.
|
Gut Liver
|
2014
|
1.07
|
|
10
|
Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response.
|
Hepatology
|
2014
|
1.05
|
|
11
|
Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review.
|
Can J Gastroenterol Hepatol
|
2014
|
1.00
|
|
12
|
Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents.
|
PLoS Pathog
|
2014
|
0.98
|
|
13
|
Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir.
|
Aliment Pharmacol Ther
|
2015
|
0.97
|
|
14
|
Safety and efficacy of protease inhibitor based combination therapy in a single-center "real-life" cohort of 110 patients with chronic hepatitis C genotype 1 infection.
|
BMC Gastroenterol
|
2014
|
0.94
|
|
15
|
Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals.
|
Ann Gastroenterol
|
2015
|
0.92
|
|
16
|
Telaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated hepatitis C virus patients.
|
World J Hepatol
|
2014
|
0.91
|
|
17
|
Managing HIV/hepatitis C co-infection in the era of direct acting antivirals.
|
BMC Med
|
2013
|
0.89
|
|
18
|
Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights.
|
Nat Rev Gastroenterol Hepatol
|
2016
|
0.88
|
|
19
|
Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study.
|
Transplantation
|
2015
|
0.88
|
|
20
|
Hepatitis C cirrhosis: New perspectives for diagnosis and treatment.
|
World J Hepatol
|
2015
|
0.87
|
|
21
|
Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease.
|
World J Hepatol
|
2015
|
0.86
|
|
22
|
Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future.
|
Front Pharmacol
|
2016
|
0.85
|
|
23
|
SASLT guidelines: Update in treatment of Hepatitis C virus infection.
|
Saudi J Gastroenterol
|
2016
|
0.85
|
|
24
|
Management of hepatitis C infection before and after liver transplantation.
|
World J Gastroenterol
|
2015
|
0.85
|
|
25
|
Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis.
|
PLoS One
|
2014
|
0.84
|
|
26
|
Treatment decisions and contemporary versus pending treatments for hepatitis C.
|
Nat Rev Gastroenterol Hepatol
|
2013
|
0.84
|
|
27
|
Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?
|
PLoS One
|
2015
|
0.84
|
|
28
|
Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin.
|
J Clin Microbiol
|
2015
|
0.83
|
|
29
|
First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohort.
|
Virol J
|
2015
|
0.83
|
|
30
|
Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patients.
|
Antimicrob Agents Chemother
|
2014
|
0.82
|
|
31
|
Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy.
|
Antivir Ther
|
2014
|
0.82
|
|
32
|
Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving Telaprevir.
|
PLoS One
|
2014
|
0.82
|
|
33
|
Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C.
|
Ann Gastroenterol
|
2016
|
0.81
|
|
34
|
Natural history, treatment and prevention of hepatitis C recurrence after liver transplantation: past, present and future.
|
World J Gastroenterol
|
2014
|
0.81
|
|
35
|
Hepatitis C virus reinfection after liver transplantation: is there a role for direct antiviral agents?
|
World J Gastroenterol
|
2014
|
0.81
|
|
36
|
Results of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C.
|
Int J Circumpolar Health
|
2016
|
0.81
|
|
37
|
An update on the treatment of genotype-1 chronic hepatitis C infection: lessons from recent clinical trials.
|
Ther Adv Infect Dis
|
2013
|
0.81
|
|
38
|
Liver transplantation for viral hepatitis in 2015.
|
World J Gastroenterol
|
2016
|
0.80
|
|
39
|
Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy.
|
Liver Int
|
2015
|
0.80
|
|
40
|
Triple Therapy with First Generation Protease Inhibitors for Hepatitis C Markedly Impairs Function of Neutrophil Granulocytes.
|
PLoS One
|
2016
|
0.80
|
|
41
|
SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patients.
|
Antimicrob Agents Chemother
|
2014
|
0.80
|
|
42
|
Antiviral therapies for chronic hepatitis C virus infection with cirrhosis.
|
World J Hepatol
|
2015
|
0.80
|
|
43
|
Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens.
|
World J Gastroenterol
|
2015
|
0.80
|
|
44
|
Chronic hepatitis C genotype 1 treatment roadmap for resource constrained settings.
|
World J Gastroenterol
|
2015
|
0.80
|
|
45
|
Strategies for treating chronic HCV infection in patients with cirrhosis: latest evidence and clinical outcomes.
|
Ther Adv Chronic Dis
|
2015
|
0.80
|
|
46
|
Recurrent hepatitis C after liver transplant.
|
World J Gastroenterol
|
2014
|
0.79
|
|
47
|
Dermatologic adverse events of protease inhibitor-based combination therapy in patients with chronic hepatitis C.
|
J Dermatol Case Rep
|
2014
|
0.79
|
|
48
|
Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection.
|
Clin Mol Hepatol
|
2016
|
0.79
|
|
49
|
Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis.
|
Antimicrob Agents Chemother
|
2014
|
0.79
|
|
50
|
Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea.
|
Clin Mol Hepatol
|
2015
|
0.79
|
|
51
|
Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia.
|
Liver Int
|
2015
|
0.79
|
|
52
|
Chronic hepatitis C genotype 1 virus: who should wait for treatment?
|
World J Gastroenterol
|
2014
|
0.78
|
|
53
|
Programmed death-1/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapy.
|
World J Hepatol
|
2015
|
0.78
|
|
54
|
Management of Hepatitis C Before and After Liver Transplantation in the Era of Rapidly Evolving Therapeutic Advances.
|
J Clin Transl Hepatol
|
2014
|
0.78
|
|
55
|
Prediction of Sustained Virological Response to Telaprevir-Based Triple Therapy Using Viral Response within 2 Weeks.
|
Hepat Res Treat
|
2014
|
0.78
|
|
56
|
IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients.
|
World J Gastroenterol
|
2014
|
0.77
|
|
57
|
Nationwide experience of treatment with protease inhibitors in chronic hepatitis C patients in Denmark: identification of viral resistance mutations.
|
PLoS One
|
2014
|
0.77
|
|
58
|
Boceprevir early-access for advanced-fibrosis/cirrhosis in Asia-Pacific hepatitis C virus genotype 1 non-responders/relapsers.
|
World J Gastroenterol
|
2015
|
0.77
|
|
59
|
Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection.
|
Ther Clin Risk Manag
|
2014
|
0.77
|
|
60
|
Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis.
|
PLoS One
|
2015
|
0.77
|
|
61
|
Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: The quality-adjusted cost of care.
|
Medicine (Baltimore)
|
2016
|
0.77
|
|
62
|
Baseline MELD score predicts hepatic decompensation during antiviral therapy in patients with chronic hepatitis C and advanced cirrhosis.
|
PLoS One
|
2013
|
0.76
|
|
63
|
A Model-Based Illustrative Exploratory Approach to Optimize the Dosing of Peg-IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple Therapy.
|
CPT Pharmacometrics Syst Pharmacol
|
2014
|
0.76
|
|
64
|
Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients.
|
PLoS One
|
2015
|
0.76
|
|
65
|
Hepatitis C: New challenges in liver transplantation.
|
World J Gastroenterol
|
2015
|
0.76
|
|
66
|
Two-Year Follow-Up Analysis of Telaprevir-Based Antiviral Triple Therapy for HCV Recurrence in Genotype 1 Infected Liver Graft Recipients as a First Step towards Modern HCV Therapy.
|
Hepat Res Treat
|
2016
|
0.75
|
|
67
|
Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma.
|
World J Gastroenterol
|
2016
|
0.75
|
|
68
|
Comment to "Telaprevir Experience From Turkey".
|
Hepat Mon
|
2015
|
0.75
|
|
69
|
Hepatitis C in Argentina: epidemiology and treatment.
|
Hepat Med
|
2014
|
0.75
|
|
70
|
Patient adherence issues in the treatment of hepatitis C.
|
Patient Prefer Adherence
|
2014
|
0.75
|
|
71
|
Pharmacokinetics, safety, and tolerability of faldaprevir in patients with renal impairment.
|
Antimicrob Agents Chemother
|
2014
|
0.75
|
|
72
|
Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study.
|
PLoS One
|
2015
|
0.75
|
|
73
|
Boceprevir for chronic HCV genotype 1 infection in treatment-experienced patients with severe fibrosis or cirrhosis: The Greek real-life experience.
|
Ann Gastroenterol
|
2015
|
0.75
|
|
74
|
Patient Characteristics, Safety, and Tolerability with Telaprevir Treatment for HCV in the Clinic: a Retrospective, Multicenter Study.
|
J Clin Transl Hepatol
|
2014
|
0.75
|
|
75
|
Limited Fibrosis Progression but Significant Mortality in Patients Ineligible for Interferon-Based Hepatitis C Therapy.
|
J Clin Exp Hepatol
|
2016
|
0.75
|
|
76
|
Telaprevir and ribavirin interaction: higher ribavirin levels are not only due to renal dysfunction during triple therapy.
|
Antimicrob Agents Chemother
|
2015
|
0.75
|
|
77
|
Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis: A Multicenter Cohort Study.
|
Medicine (Baltimore)
|
2015
|
0.75
|
|
78
|
Aplastic anemia and severe pancytopenia during treatment with peg-interferon, ribavirin and telaprevir for chronic hepatitis C.
|
World J Gastroenterol
|
2015
|
0.75
|
|
79
|
A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3.
|
Springerplus
|
2016
|
0.75
|
|
80
|
Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study.
|
World J Gastroenterol
|
2015
|
0.75
|
|
81
|
Treatment Selection Choices Should Not Be Based on Benefits or Costs Alone: A Head-to-Head Randomized Controlled Trial of Antiviral Drugs for Hepatitis C.
|
PLoS One
|
2016
|
0.75
|
|
82
|
Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis.
|
World J Gastroenterol
|
2015
|
0.75
|
|
83
|
Virological response and resistance mutations to NS3/4A inhibitors in hepatitis C virus-human immunodeficiency virus coinfection.
|
World J Hepatol
|
2015
|
0.75
|